Linezolid

ANDA 78987, held by Glenmark Speclt. Linezolid.

As of Nov 15, 2026, ANDA 78987 (Linezolid), held by Glenmark Speclt, was first approved by FDA on Dec 21, 2015, with 9 approved supplements and 0 published complete response letters.

First approved: Dec 21, 2015
Supplements approved: 9
Complete response letters: 0

Approvals and New Uses

The original application and every efficacy supplement, newest first; all 10 submissions below

Date	Submission	Status	Documents
Dec 21, 2015	Original application	Approved	None posted

Products

1 strengths and forms

Product	Active ingredient	Marketing
Linezolid600MG · tablet;oral	Linezolid	Rx

All 10 submissions, including labeling and manufacturing supplements


Sep 23, 2024	Supplement 5Labeling · Standard review	Approved	None posted
Sep 23, 2024	Supplement 6Labeling · Standard review	Approved	None posted
Sep 23, 2024	Supplement 7Labeling · Standard review	Approved	None posted
Sep 23, 2024	Supplement 8Labeling · Standard review	Approved	None posted
Sep 23, 2024	Supplement 9Labeling · Standard review	Approved	None posted
Sep 23, 2024	Supplement 10Labeling · Standard review	Approved	None posted
Dec 31, 2018	Supplement 1Labeling · Standard review	Approved	None posted
Dec 31, 2018	Supplement 3Labeling · Standard review	Approved	None posted
Dec 31, 2018	Supplement 4Labeling · Standard review	Approved	None posted
Dec 21, 2015	Original application	Approved	None posted

Identifiers

Application: ANDA 78987
Drugs@FDA: Overview at FDA
Company: Glenmark Specialty

Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters